Peer Review History

Original SubmissionFebruary 17, 2023
Decision Letter - Silvia Fiorelli, Editor

PONE-D-23-04634Assessing swallowing disorders in adults on high-flow nasal cannula in critical and non-critical care settings. A protocol for a scoping reviewPLOS ONE

Dear Dr. Gutierrez-Arias,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

ACADEMIC EDITOR: Please revise the manuscript according to the reviewers comments.

Please submit your revised manuscript by Aug 13 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Silvia Fiorelli

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following financial disclosure: 

The funders did not and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. 

At this time, please address the following queries:

a) Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution. 

b) State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

c) If any authors received a salary from any of your funders, please state which authors and which funders.

d) If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

3. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript. 

4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions?

The research question outlined is expected to address a valid academic problem or topic and contribute to the base of knowledge in the field.

Reviewer #1: Partly

Reviewer #2: Partly

**********

2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses?

The manuscript should describe the methods in sufficient detail to prevent undisclosed flexibility in the experimental procedure or analysis pipeline, including sufficient outcome-neutral conditions (e.g. necessary controls, absence of floor or ceiling effects) to test the proposed hypotheses and a statistical power analysis where applicable. As there may be aspects of the methodology and analysis which can only be refined once the work is undertaken, authors should outline potential assumptions and explicitly describe what aspects of the proposed analyses, if any, are exploratory.

Reviewer #1: Partly

Reviewer #2: Partly

**********

3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable?

Descriptions of methods and materials in the protocol should be reported in sufficient detail for another researcher to reproduce all experiments and analyses. The protocol should describe the appropriate controls, sample size calculations, and replication needed to ensure that the data are robust and reproducible.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors described where all data underlying the findings will be made available when the study is complete?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception, at the time of publication. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics.

You may also provide optional suggestions and comments to authors that they might find helpful in planning their study.

(Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: 1. Please descibe in full the methodology. Will any reference manager be used? What is the time frame? How is the distinction between critical and non-critical setting done? Are there two or three researchers engaged in the analysis of publications?

2. Figure 1 is not mentioned int the text, it also does not add any value to the publication.

3. The protocol requires english editing.

4. Line 32 and line 33 - two consecutive sentences start with "However". Please replace it with a different vocabulary.

5. Line 40 - the authors declare the research in any language will be considered. How are the authors planning to perform translation to understant the full context of the publication?

6. Line 44, line 166 - the term "hurt" seems to be ambiguous, please consider different term.

7. Line 45-48 - this sentence is too long and unclear, please consider rephrasing.

9. Line 56 - please consider adding a subject, e.g "especially in patients with hypoxemic respiratory failure" instead of effectivenes in [...], especially in hypoxemic respiratory failure

9. Line 59 - please consider using a different term instead of "known", "set" or "planned" seems to be more adequate verb here

10. Line 63 0 please consider adding "its" or "HFNC" before the word "use"

11. Line 70 - none of the cited studies [19-21] concerns newborns. In study 19 & 20 pediatric population is being studied, however very few newborns are included. Study 21 reffers mainly to adults.

12. Line 76 - please refrain from repeating an adjective "different" in one sentence.

13. Line 77-78 - the sentence "The flow used in HFNC needed to trigger them in adults with and without diseases in incomprehensible

14. Line 98 - 99 - repeated phrase "through the Ovid platform"

15. Line 116-118 phrase "adults [...] who may be healthy or have a disease requiring acute or chronic use of HFNC" is unclear. Are patents requiring HFNC without any underlying diseases or with acute or chronic resp. diseases included? Please clarify

16. Line 166-167 - "altering the preathing and swallowing pattern" - is altering the synchronization of breathing and swallowing ment?

17. Line 168-170 - the sentence "This could be explained [...]." is unclear, the term "vitellus" stands for an egg yolk, what was ment?

Reviewer #2: The authors present the protocol for a narrative review on swallowing disorders in adult patients with ongoing high flow nasal therapy. Authors properly state pitfalls of previous similar studies: not systematic searches or not adequately summarized.

Authors aim to review the frequency of swallowing disorders and scales used for assessment. Some confoundings are commented: flow, oxygen fraction, device, location of patients (critical vs non-critical), age.

My main concern is about management of these confoundings to present the results. Could authors detail?

Authors state that aspiration pneumonia has been associated with HFNC, but a cite is lacking.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Joanna Maria Jassem-Bobowicz

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Journal Requirements:

Comment: 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming…

Response: The manuscript was edited according to PLOS ONE style requirements.

Comment: At this time, please address the following queries:

a) Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

b) State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

c) If any authors received a salary from any of your funders, please state which authors and which funders.

d) If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

Response: In the “Rebuttal Letter” we requested the change of the funding statement to “The authors received no specific funding for this work.”

Comment: 3. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript.

Response: The ethics statement was moved to the Methods section and removed from other parts of the manuscript.

Comment: 4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

Response: Our Supporting Information subheading was included at the end of the manuscript and cited in the Methods section.

Reviewer #1

Comment: Please descibe in full the methodology. Will any reference manager be used? What is the time frame? How is the distinction between critical and non-critical setting done? Are there two or three researchers engaged in the analysis of publications?

Response: Thank you for your questions. Several methodological clarifications have been added to the manuscript:

* “Once the studies had been searched, duplicates will be removed using the Mendeley® (Mendeley Desktop Version 1.19.8 - Elsevier Inc.) reference manager and the Rayyan® app”.

* “Data extraction will be carried out by 4 researchers in pairs of one experienced and one novice reviewer”.

* “Findings will be reported for all studies and separated by those conducted in critical and non-critical settings. The critical setting will comprise the intensive critical units, and the non-critical setting will comprise all other units and the out-of-hospital”.

Comment: Figure 1 is not mentioned int the text, it also does not add any value to the publication.

Response: Thank you for your comment. We have replaced the figure with a table to detail the data that will be extracted from the included studies.

Comment: The protocol requires english editing.

Response: The protocol was reviewed and edited by a native English speaker.

Comment: Line 32 and line 33 - two consecutive sentences start with "However". Please replace it with a different vocabulary.

Response: Thank you for your comment. “However” has been changed to “Nevertheless”.

Comment: Line 40 - the authors declare the research in any language will be considered. How are the authors planning to perform translation to understant the full context of the publication?

Response: Thank you for your comment. In the Methods section, the following idea was added:

“For the translation of studies published in languages other than English and Spanish, researchers who are native speakers of the language of publication will be contacted to resolve doubts regarding the general context of the study.”

Comment: Line 44, line 166 - the term "hurt" seems to be ambiguous, please consider different term.

Response: Thank you for your comment.

Comment: Line 45-48 - this sentence is too long and unclear, please consider rephrasing.

Response: The term "hurt" was changed to "impair" in both sections of the manuscript.

Comment: Line 56 - please consider adding a subject, e.g "especially in patients with hypoxemic respiratory failure" instead of effectivenes in [...], especially in hypoxemic respiratory failure.

Response: Thanks for the suggestion. The sentence was replaced by “A number of studies have reported the effectiveness of HFNC”.

Comment: Line 59 - please consider using a different term instead of "known", "set" or "planned" seems to be more adequate verb here

Response: Thanks for the suggestion. “Known” has been changed to “planned”.

Comment: Line 63 0 please consider adding "its" or "HFNC" before the word "use"

Response: Thanks for the suggestion. Added the term “its”.

Comment: Line 70 - none of the cited studies [19-21] concerns newborns. In study 19 & 20 pediatric population is being studied, however very few newborns are included. Study 21 reffers mainly to adults.

Response: Thank you for your comment. Reference 21 was deleted, and the sentence was left as follows:

“Most of the research related to the research question posed in this protocol has focused on pediatrics, probably because the evidence supports the use of HFNC in this publication.”

Comment: Line 76 - please refrain from repeating an adjective "different" in one sentence.

Response: Thank you for your comment. “different” has been changed to “diverse”.

Comment: Line 77-78 - the sentence "The flow used in HFNC needed to trigger them in adults with and without diseases in incomprehensible

Response: The phrase was deleted.

Comment: Line 98 - 99 - repeated phrase "through the Ovid platform"

Response: According to the PRISMA-S and PRESS declaration, the search platform is required for each database. In this case, we report that we will use OVID to search MEDLINE and Embase, as well as other platforms for the remaining databases.

Comment: Line 116-118 phrase "adults [...] who may be healthy or have a disease requiring acute or chronic use of HFNC" is unclear. Are patents requiring HFNC without any underlying diseases or with acute or chronic resp. diseases included? Please clarify

Response: Thank you for your comment. Let us explain the next sentence better:

“These may be healthy people who have voluntarily participated in studies to evaluate the use of HFNC or have a disease requiring acute or chronic use of HFNC.”

Comment: Line 166-167 - "altering the preathing and swallowing pattern" - is altering the synchronization of breathing and swallowing ment?

Response: Thanks for the suggestion. “Altering the breathing and swallowing pattern” was changed by “synchronization of breathing and swallowing.”

Comment: Line 168-170 - the sentence "This could be explained [...]." is unclear, the term "vitellus" stands for an egg yolk, what was ment?

Response: We change the term "vitellus" to “vellum”.

Reviewer #1

Comment: Some confoundings are commented: flow, oxygen fraction, device, location of patients (critical vs non-critical), age. My main concern is about management of these confoundings to present the results. Could authors detail?

Response: The purpose of a scoping review is to describe what the literature says or what research has been done on a specific topic. Our aim is not to provide recommendations for clinical practice, which is rather the aim of systematic reviews and clinical practice guidelines, but to identify what has been studied regarding the possible association between the use of HFNC and swallowing disorders. Therefore, our study will serve to identify gaps in knowledge and provide recommendations for future research.

All possible variables that could confound the relationship between swallowing disorder and HFNC use will be discussed for future primary studies to consider.

Comment: Authors state that aspiration pneumonia has been associated with HFNC, but a cite is lacking.

Response: A reference was added to support the possibility that the use of HFNC may generate aspiration.

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Silvia Fiorelli, Editor

Assessing swallowing disorders in adults on high-flow nasal cannula in critical and non-critical care settings. A scoping review protocol

PONE-D-23-04634R1

Dear Dr. Ruvistay Gutierrez-Arias,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Silvia Fiorelli

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Congratulations to the authors and thanks to the reviewers for the suggestions provided which really helped improve the quality of the manuscript

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions?

The research question outlined is expected to address a valid academic problem or topic and contribute to the base of knowledge in the field.

Reviewer #2: Yes

Reviewer #3: Yes

**********

2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses?

The manuscript should describe the methods in sufficient detail to prevent undisclosed flexibility in the experimental procedure or analysis pipeline, including sufficient outcome-neutral conditions (e.g. necessary controls, absence of floor or ceiling effects) to test the proposed hypotheses and a statistical power analysis where applicable. As there may be aspects of the methodology and analysis which can only be refined once the work is undertaken, authors should outline potential assumptions and explicitly describe what aspects of the proposed analyses, if any, are exploratory.

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable?

Descriptions of methods and materials in the protocol should be reported in sufficient detail for another researcher to reproduce all experiments and analyses. The protocol should describe the appropriate controls, sample size calculations, and replication needed to ensure that the data are robust and reproducible.

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Have the authors described where all data underlying the findings will be made available when the study is complete?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception, at the time of publication. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics.

You may also provide optional suggestions and comments to authors that they might find helpful in planning their study.

(Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: All my comments were adequately answered. The protocol has been clearly improved. I have no further comments.

Reviewer #3: Many thanks for asking me to review the above Scoping Reveiw.

The authors aimed to explore the literature to identify and map the evidence regarding the frequency and methods of assessing swallowing disorders in adult HFNC users in critical and non critical units.

It is a well written manuscript and the findings, provide insight into the methodological characteristics, the frequency of swallowing disorders, and the instruments used to assess their presence.

The authors have clearly and precisely responded to the comments of previous Reviewers, thus clarifying some "grey" areas of the Study's methodology.

Not having to point out any additional comment or correction, I think the Manuscript should be published in its current form.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Reviewer #3: No

**********

Formally Accepted
Acceptance Letter - Silvia Fiorelli, Editor

PONE-D-23-04634R1

Assessing swallowing disorders in adults on high-flow nasal cannula in critical and non-critical care settings. A scoping review protocol

Dear Dr. Gutierrez-Arias:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Silvia Fiorelli

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .